Lamotrigine

• 

  Subject Areas on Research

  • A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. 
  • Adjunctive lamotrigine for partial seizures in patients aged 1 to 24 months. 
  • Bidirectional interaction of valproate and lamotrigine in healthy subjects. 
  • Case report: Successful riluzole augmentation therapy in treatment-resistant bipolar depression following the development of rash with lamotrigine. 
  • Comments on "Addition of lamotrigine to valproic acid: a successful outcome in a case of rapid-cycling bipolar affective disorder". 
  • Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. 
  • Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). 
  • Derivation of the SPAN, a brief diagnostic screening test for post-traumatic stress disorder. 
  • Discovery and development of lamotrigine for bipolar disorder: a story of serendipity, clinical observations, risk taking, and persistence. 
  • Dramatic Response After Lamotrigine in a Patient With Epileptic Encephalopathy and a De NovoCACNA1A Variant. 
  • Efficacy, tolerability, and kinetics of lamotrigine in infants. 
  • Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions. 
  • Improved sexual function in three men taking lamotrigine for epilepsy. 
  • Increased Antiseizure Effectiveness with Tiagabine Combined with Sodium Channel Antagonists in Mice Exposed to Hyperbaric Oxygen. 
  • International prescribing patterns for mood illness: the International Mood Network (IMN). 
  • Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. 
  • Lamotrigine in absence and primary generalized epilepsies. 
  • Lamotrigine-associated rash: to rechallenge or not to rechallenge? 
  • Lamotrigine-induced blepharospasm. 
  • Long-term tolerability and efficacy of lamotrigine in infants 1 to 24 months old. 
  • Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures. 
  • Motor cortex excitability after vagus nerve stimulation in major depression. 
  • Oculogyric crises secondary to lamotrigine overdosage. 
  • Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group. 
  • Potential hepatotoxicity of lamotrigine. 
  • Routine therapeutic monitoring of lamotrigine in epileptic patients using a simple and rapid high performance liquid chromatographic technique. 
  • Safety and tolerability of lamotrigine: results from 12 placebo-controlled clinical trials and clinical implications. 
  • TUBULOINTERSTITIAL NEPHRITIS AND UVEITIS SYNDROME WITH A PRIMARY PRESENTATION OF ACUTE POSTERIOR MULTIFOCAL PLACOID PIGMENT EPITHELIOPATHY. 
  • The Impact of Pharmacokinetic Interactions With Eslicarbazepine Acetate Versus Oxcarbazepine and Carbamazepine in Clinical Practice. 
  • The effect of cognitive functioning on treatment attendance and adherence in comorbid bipolar disorder and cocaine dependence. 
  • The name game: lamivudine-lamotrigine dispensing error presenting as human immunodeficiency virus-associated fever of unknown origin. 
  • Use of Therapeutic Drug Monitoring, Electronic Health Record Data, and Pharmacokinetic Modeling to Determine the Therapeutic Index of Phenytoin and Lamotrigine. 
  • Use of lamotrigine in a patient with a clozapine-related seizure. 
  • Utility of the lethargic (lh/lh) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures.